ATechniczna
http://www.parkiet.com/artykul/31,14709 ... tfela.html
Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
REKLAMA
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck & Co. Inc. (NYSE: MRK) reported its third-quarter financial results before the markets opened on Friday. The pharma giant said that it had $1.11 in earnings per share (EPS) and $10.54 billion in revenue, which compares with consensus estimates from Thomson Reuters of $1.03 in EPS on revenue of $10.55 billion. The same period of last year reportedly had EPS of $1.07 and $10.54 billion in revenue.
http://247wallst.com/healthcare-busines ... uda-sales/
http://247wallst.com/healthcare-busines ... uda-sales/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Soars as Lung Cancer Study Meets Goals
https://www.thestreet.com/story/1445095 ... goals.html
https://www.thestreet.com/story/1445095 ... goals.html
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Sales Miss, But Earnings, 2018 Revenue Outlook Strong
https://www.investors.com/news/technolo ... ok-strong/
https://www.investors.com/news/technolo ... ok-strong/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Sees Big Boost From Keytruda in Q4
http://247wallst.com/consumer-electroni ... -together/
http://247wallst.com/consumer-electroni ... -together/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates
https://247wallst.com/healthcare-busine ... val-rates/
https://247wallst.com/healthcare-busine ... val-rates/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Underwhelms Despite Beating Earnings
https://247wallst.com/healthcare-busine ... -earnings/
https://247wallst.com/healthcare-busine ... -earnings/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Drug giant Merck & Co. Inc. (NYSE: MRK) reported third-quarter 2018 results before markets opened Thursday. The company reported adjusted diluted earnings per share (EPS) of $1.19 and revenues of $10.79 billion. In the same period a year ago, Merck reported EPS of $1.11 on revenues of $10.33 billion. Third-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $1.14 and $10.88 billion in revenues.
On a GAAP basis, Merck posted EPS of $0.73, which includes acquisition- and divestiture-related costs, restructuring costs, a charge of $420 million related to the termination of a collaboration agreement with Samsung Bioepis (Samsung) for insulin glargine and certain other items.
Net income on a GAAP basis totaled $1.95 billion, while non-GAAP net income totaled $3.18 billion. Non-GAAP net income excludes $651 million in costs related to acquisitions and divestitures, $149 million in restructuring costs and $431 million in certain other items.
Pharmaceutical sales were up 5% year over year. Excluding currency exchange effects, sales were up 7%. The company’s Keytruda cancer drug posted a sales increase of 80% in the quarter, ringing up $1.89 billion in sales. Other cancer drugs, Gardasil and Gardasil 9, posted a 55% sales gain to $1.05 billion.
https://247wallst.com/healthcare-busine ... -for-fy18/
On a GAAP basis, Merck posted EPS of $0.73, which includes acquisition- and divestiture-related costs, restructuring costs, a charge of $420 million related to the termination of a collaboration agreement with Samsung Bioepis (Samsung) for insulin glargine and certain other items.
Net income on a GAAP basis totaled $1.95 billion, while non-GAAP net income totaled $3.18 billion. Non-GAAP net income excludes $651 million in costs related to acquisitions and divestitures, $149 million in restructuring costs and $431 million in certain other items.
Pharmaceutical sales were up 5% year over year. Excluding currency exchange effects, sales were up 7%. The company’s Keytruda cancer drug posted a sales increase of 80% in the quarter, ringing up $1.89 billion in sales. Other cancer drugs, Gardasil and Gardasil 9, posted a 55% sales gain to $1.05 billion.
https://247wallst.com/healthcare-busine ... -for-fy18/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck Clears a Low Hurdle for Q4 Earnings
When Merck & Co., Inc. (NYSE: MRK) released its fourth-quarter financial results after the markets closed on Thursday, the pharma giant said that it had $1.04 in earnings per share (EPS) and $11 billion in revenue. That compared with consensus estimates of $1.03 in EPS and $10.94 billion in revenue, as well as the $0.98 per share and $10.43 billion posted in the same period of last year.
In the latest quarter, worldwide sales increased 5% from the fourth quarter of 2017, including a 3% negative impact from foreign exchange.
Keytruda, the firm’s main cancer treatment, brought in $2.15 billion in the quarter, up 88% year over year. It generated $7.17 billion in 2018, up by the same percentage, and now accounts for more than 20% of the company’s revenue.
Growth in oncology was driven by a significant increase in sales of Keytruda, reflecting the strong momentum for the treatment of patients with non-small cell lung cancer and the company’s continued launches with new indications globally.
Merck reported on a few of the major products as follows:
Januvia/Janumet net sales decreased 4% to $1.47 billion.
Gardasil/Gardasil 9 net sales increased 32% to $835 million.
Proquad, M-M-R II and Varivax net sales increased 13% to $455 million.
Pneumovax 23 net sales increased 23% to $322 million.
Isentress/Isentress HD net sales decreased 9% to $280 million.
Looking ahead to the 2019 full year, the firm expects to see EPS in the range of $4.57 to $4.72 and worldwide sales between $43.2 billion and $44.7 billion. Consensus estimates call for $4.69 in EPS and $44.54 billion in revenue for the year.
https://247wallst.com/healthcare-busine ... -earnings/
When Merck & Co., Inc. (NYSE: MRK) released its fourth-quarter financial results after the markets closed on Thursday, the pharma giant said that it had $1.04 in earnings per share (EPS) and $11 billion in revenue. That compared with consensus estimates of $1.03 in EPS and $10.94 billion in revenue, as well as the $0.98 per share and $10.43 billion posted in the same period of last year.
In the latest quarter, worldwide sales increased 5% from the fourth quarter of 2017, including a 3% negative impact from foreign exchange.
Keytruda, the firm’s main cancer treatment, brought in $2.15 billion in the quarter, up 88% year over year. It generated $7.17 billion in 2018, up by the same percentage, and now accounts for more than 20% of the company’s revenue.
Growth in oncology was driven by a significant increase in sales of Keytruda, reflecting the strong momentum for the treatment of patients with non-small cell lung cancer and the company’s continued launches with new indications globally.
Merck reported on a few of the major products as follows:
Januvia/Janumet net sales decreased 4% to $1.47 billion.
Gardasil/Gardasil 9 net sales increased 32% to $835 million.
Proquad, M-M-R II and Varivax net sales increased 13% to $455 million.
Pneumovax 23 net sales increased 23% to $322 million.
Isentress/Isentress HD net sales decreased 9% to $280 million.
Looking ahead to the 2019 full year, the firm expects to see EPS in the range of $4.57 to $4.72 and worldwide sales between $43.2 billion and $44.7 billion. Consensus estimates call for $4.69 in EPS and $44.54 billion in revenue for the year.
https://247wallst.com/healthcare-busine ... -earnings/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck increases in its dividend, upping the quarterly dividend 10.91% from $0.55 to $0.61 DY 2.75%
https://www.dividend.com/news/2019/12/1 ... -dividend/
https://www.dividend.com/news/2019/12/1 ... -dividend/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Merck profit beats, coronavirus uncertainty weighs on forecast
(Reuters) - Merck & Co Inc (N:MRK) beat analysts' estimates for quarterly profit on Tuesday on strong demand for its blockbuster cancer drug, Keytruda, but expects coronavirus-led lockdowns to weigh on the treatment's sales in the next few quarters.
Merck, which lowered its full-year 2020 profit forecast, said roughly 66% of its revenue is made up of drugs that are administered at a doctor's office, including Keytruda, and social distancing measures are hitting their sales.
"The company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place," Merck said.
The company also said it was suspending its share buyback program.
Sales of Keytruda jumped 45% in the first quarter to $3.28 billion.
Net income attributable to shareholders rose to $3.22 billion, or $1.26 per share, in the quarter from $2.92 billion, or $1.12 per share, a year earlier.
Excluding items, Merck earned $1.50 per share, beating estimates of $1.34 per share, according to IBES data from Refinitiv.
The company now expects full-year adjusted profit of $5.17 to $5.37 per share, down from its prior estimate of $5.62 to $5.77 per share.
https://www.investing.com/news/stock-ma ... ty-2153095
(Reuters) - Merck & Co Inc (N:MRK) beat analysts' estimates for quarterly profit on Tuesday on strong demand for its blockbuster cancer drug, Keytruda, but expects coronavirus-led lockdowns to weigh on the treatment's sales in the next few quarters.
Merck, which lowered its full-year 2020 profit forecast, said roughly 66% of its revenue is made up of drugs that are administered at a doctor's office, including Keytruda, and social distancing measures are hitting their sales.
"The company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place," Merck said.
The company also said it was suspending its share buyback program.
Sales of Keytruda jumped 45% in the first quarter to $3.28 billion.
Net income attributable to shareholders rose to $3.22 billion, or $1.26 per share, in the quarter from $2.92 billion, or $1.12 per share, a year earlier.
Excluding items, Merck earned $1.50 per share, beating estimates of $1.34 per share, according to IBES data from Refinitiv.
The company now expects full-year adjusted profit of $5.17 to $5.37 per share, down from its prior estimate of $5.62 to $5.77 per share.
https://www.investing.com/news/stock-ma ... ty-2153095
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
UNDERVALUED DIVIDEND GROWTH STOCK OF THE WEEK
Merck & Co., Inc. (MRK)
https://dailytradealert.com/2020/06/21/ ... o-inc-mrk/
Merck & Co., Inc. (MRK)
https://dailytradealert.com/2020/06/21/ ... o-inc-mrk/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny
Dow Jones Giant Merck Inks A New Deal In Lung Cancer — And Shares Pop
Novocure (NVCR) and Dow Jones pharma giant Merck (MRK) announced a collaboration in lung cancer treatment Wednesday — prodding shares of Novocure and Merck stock to pop.
The collaboration will study a combination of Novocure's medical device with Merck's blockbuster drug Keytruda in patients with a form of lung cancer. Novocure's medical devices use electrical fields tuned to specific frequencies to disrupt cell division and block tumor growth.
The companies will run a Phase 2 study in patients with non-small cell lung cancer, which accounts for 85% of all lung cancers. They plan to enroll 66 patients in the cancer treatment test and expect to begin in the second half of 2020, Novocure said in a news release.
Novocure Executive Chairman William Doyle noted there's early evidence showing the benefit of adding the company's so-called "tumor-treating fields" to a drug like Keytruda. Keytruda inhibits a connection involving a protein called PD-1 to help unmask tumor cells.
...
https://www.investors.com/news/technolo ... -novocure/
Novocure (NVCR) and Dow Jones pharma giant Merck (MRK) announced a collaboration in lung cancer treatment Wednesday — prodding shares of Novocure and Merck stock to pop.
The collaboration will study a combination of Novocure's medical device with Merck's blockbuster drug Keytruda in patients with a form of lung cancer. Novocure's medical devices use electrical fields tuned to specific frequencies to disrupt cell division and block tumor growth.
The companies will run a Phase 2 study in patients with non-small cell lung cancer, which accounts for 85% of all lung cancers. They plan to enroll 66 patients in the cancer treatment test and expect to begin in the second half of 2020, Novocure said in a news release.
Novocure Executive Chairman William Doyle noted there's early evidence showing the benefit of adding the company's so-called "tumor-treating fields" to a drug like Keytruda. Keytruda inhibits a connection involving a protein called PD-1 to help unmask tumor cells.
...
https://www.investors.com/news/technolo ... -novocure/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 2 gości